Table 2.
Percent adherence and clinical outcomes data by intervention arm
| EDM % doses taken | All participants N = 204 | SC n = 65 | MI-CBT n = 70 | MI-CBT/mDOT n = 69 |
|---|---|---|---|---|
| M (SD) | M (SD) | M (SD) | M (SD) | |
| 12 weeks | 78.5 (29.8) | 75.3 (32.6) | 77.6 (32.1) | 82.5 (23.6) |
| 24 weeks | 73.0 (32.2) | 73.5 (32.5) | 70.9 (34.5) | 74.4 (30.1) |
| 36 weeks | 70.3 (32.4) | 74.7 (30.3) | 69.3 (33.1) | 67.2 (33.7) |
| 48 weeks | 69.6 (32.4) | 75.5 (29.7) | 69.3 (32.6) | 64.6 (34.4) |
| EDM % doses taken on time | ||||
|---|---|---|---|---|
| 12 weeks | 67.7 (31.7) | 62.3 (33.6) | 67.7 (32.7) | 73.1 (28.2) |
| 24 weeks | 61.4 (33.1) | 58.6 (33.1) | 61.1 (34.4) | 64.2 (32.0) |
| 36 weeks | 56.3 (33.5) | 57.6 (33.2) | 56.5 (34.0) | 54.9 (33.8) |
| 48 weeks | 55.5 (33.4) | 58.1 (32.5) | 56.9 (34.1) | 52.0 (34.1) |
| % Participants HIV-1 RNA VL <400 copies/mL | % (n) | % (n) | % (n) | % (n) |
|---|---|---|---|---|
| Baseline | 6.4 (204) | 4.6 (65) | 8.6 (70) | 5.8 (69) |
| 12 weeks | 70.4 (159) | 72.0 (50) | 78.2 (55) | 61.1 (54) |
| 24 weeks | 73.2 (157) | 71.4 (49) | 70.6 (51) | 77.2 (57) |
| 36 weeks | 70.2 (121) | 71.1 (38) | 72.5 (40) | 67.4 (43) |
| 48 weeks | 73.3 (135) | 73.8 (42) | 80.0 (45) | 66.7 (48) |
EDM electronic drug monitored